STC Life Successfully Differentiates a Liver Cell using its Newly Elicited Pluripotent Stem Cells without side effects by natural compound (STC-nEPS)

Seoul Economic Daily

May 21, 2014

Stem Cell Treatment & Research Institute (STRI) and 97.7 B&H Clinic under STC Life announced that they have successfully differentiated a liver cell using the Newly Elicited Pluripotent Stem Cells without side effects by natural compound (STC-nEPS) derived from human umbilical cord.

Using molecular compounds isolated from various growth factors and natural compounds, research team led by Dr. Lee Sang-hyun at STC Life enabled multiple stem cells to differentiate from Newly Elicited Pluripotent Stem Cells without side effects by natural compound (STC-nEPS) to a liver cell within a short period of time. The team induced differentiation of liver cells upon coming up with the Newly Elicited Pluripotent Stem Cells without side effects by natural compound (STC-nEPS). By tracing protein characteristic of a liver cell, the team confirmed that a liver cell was formed after five days of inducing. As a result, the research team confirmed that the Newly Elicited Pluripotent Stem Cells without side effects by natural compound STC-nEPS) showed double efficiency in eruption into a liver cell when compared to pluripotent stem cells.

Moreover in using natural compounds without genetic modification, the outcome is expected to become immediately applicable in clinical as it showed no side effects even after differentiation.

Based on this finding, STC Life is planning on a clinical to apply stem cell treatment for liver diseases. “Using this technology where we induced and differentiated the Newly Elicited Pluripotent Stem Cells without side effects by natural compound (STC-nEPS) into a liver cell, it is our vision to become leader in the world stem cell research,” remarked Kye-ho Lee, Chairman of STC Life.